Bank of New York Mellon
ENZ

Bank of New York Mellon’s Enzo Biochem, Inc. ENZ Stock Holding History

Bank of New York Mellon’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,217
Closed -$36.4K – 4335
2023
Q4 		$36.4K Hold
26,217
– – ﹤0.01% 4185
2023
Q3 		$36.7K Hold
26,217
– – ﹤0.01% 4194
2023
Q2 		$48.2K Hold
26,217
– – ﹤0.01% 4183
2023
Q1 		$63.7K Hold
26,217
– – ﹤0.01% 4147
2022
Q4 		$37.5K Sell
26,217
-61,064
-70% -$119K ﹤0.01% 4278
2022
Q3 		$194K Buy
87,281
+1,998
+2% +$4.83K ﹤0.01% 4029
2022
Q2 		$176K Sell
85,283
-4,875
-5% -$12.1K ﹤0.01% 4103
2022
Q1 		$261K Buy
90,158
+5,328
+6% +$17.1K ﹤0.01% 4095
2021
Q4 		$273K Buy
84,830
+57,522
+211% +$196K ﹤0.01% 4138
2021
Q3 		$97K Hold
27,308
– – ﹤0.01% 4337
2021
Q2 		$87K Sell
27,308
-127,303
-82% -$400K ﹤0.01% 4245
2021
Q1 		$531K Buy
154,611
+683
+0.4% +$2.12K ﹤0.01% 3658
2020
Q4 		$388K Sell
153,928
-8,935
-5% -$19.5K ﹤0.01% 3734
2020
Q3 		$343K Sell
162,863
-64,252
-28% -$153K ﹤0.01% 3664
2020
Q2 		$508K Buy
227,115
+1
+0% +$3 ﹤0.01% 3461
2020
Q1 		$575K Sell
227,114
-11,879
-5% -$29.2K ﹤0.01% 3292
2019
Q4 		$629K Sell
238,993
-2,098
-0.9% -$6.27K ﹤0.01% 3471
2019
Q3 		$867K Sell
241,091
-8,004
-3% -$28.3K ﹤0.01% 3248
2019
Q2 		$839K Buy
249,095
+25,203
+11% +$88.8K ﹤0.01% 3321
2019
Q1 		$611K Buy
223,892
+4,974
+2% +$16.3K ﹤0.01% 3455
2018
Q4 		$609K Buy
218,918
+12,371
+6% +$40.5K ﹤0.01% 3380
2018
Q3 		$850K Sell
206,547
-1
-0% -$5 ﹤0.01% 3369
2018
Q2 		$1.07M Sell
206,548
-13,083
-6% -$79.7K ﹤0.01% 3212
2018
Q1 		$1.2M Buy
219,631
+6,046
+3% +$42.6K ﹤0.01% 3112
2017
Q4 		$1.74M Sell
213,585
-18,068
-8% -$173K ﹤0.01% 2923
2017
Q3 		$2.43M Buy
231,653
+10,487
+5% +$116K ﹤0.01% 2726
2017
Q2 		$2.44M Buy
221,166
+14,719
+7% +$137K ﹤0.01% 2733
2017
Q1 		$1.73M Buy
206,447
+2,409
+1% +$17K ﹤0.01% 2932
2016
Q4 		$1.42M Buy
204,038
+26,688
+15% +$170K ﹤0.01% 3069
2016
Q3 		$903K Sell
177,350
-9,912
-5% -$59.2K ﹤0.01% 3225
2016
Q2 		$1.12M Buy
187,262
+88,602
+90% +$492K ﹤0.01% 3065
2016
Q1 		$449K Hold
98,660
– – ﹤0.01% 3485
2015
Q4 		$444K Hold
98,660
– – ﹤0.01% 3581
2015
Q3 		$313K Hold
98,660
– – ﹤0.01% 3752
2015
Q2 		$299K Sell
98,660
-54,748
-36% -$154K ﹤0.01% 3780
2015
Q1 		$452K Sell
153,408
-15,518
-9% -$50.8K ﹤0.01% 3652
2014
Q4 		$750K Sell
168,926
-16,711
-9% -$79.7K ﹤0.01% 3456
2014
Q3 		$956K Buy
185,637
+860
+0.5% +$4.59K ﹤0.01% 3318
2014
Q2 		$970K Buy
184,777
+101,320
+121% +$438K ﹤0.01% 3328
2014
Q1 		$347K Sell
83,457
-30,909
-27% -$106K ﹤0.01% 3692
2013
Q4 		$334K Sell
114,366
-89
-0.1% -$221 ﹤0.01% 3715
2013
Q3 		$288K Sell
114,455
-10,702
-9% -$25.4K ﹤0.01% 3692
2013
Q2 		$260K Buy
+125,157
New +$276K ﹤0.01% 3711

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon's ENZ Position: Q1 2024 in Review

Bank of New York Mellon sold out of Enzo Biochem, Inc. (ENZ) in Q1 2024, closing a stake of 26,217 shares — an estimated $36.4K sold.

Bank of New York Mellon first reported a position in ENZ in Q2 2013 and held it in 43 quarters. The position peaked at $2.44M in Q2 2017. 41 funds tracked by Wall St. Rank hold ENZ as of Q1 2024.

  • Bank of New York Mellon reported no remaining Enzo Biochem, Inc. position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 26,217 Enzo Biochem, Inc. shares in Q1 2024, an estimated $36.4K.
  • Bank of New York Mellon first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 43 quarters.
  • Bank of New York Mellon's Enzo Biochem, Inc. position peaked at $2.44M in Q2 2017.
  • 41 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.